Planning and Analyzing Clinical Trials with Composite Endpoints

This book addresses the most important aspects of how to plan and evaluate clinical trials with a composite primary endpoint to guarantee a clinically meaningful and valid interpretation of the results. Composite endpoints are often used as primary efficacy variables for clinical trials, particularl...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Rauch, Geraldine (Συγγραφέας, http://id.loc.gov/vocabulary/relators/aut), Schüler, Svenja (http://id.loc.gov/vocabulary/relators/aut), Kieser, Meinhard (http://id.loc.gov/vocabulary/relators/aut)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2017.
Έκδοση:1st ed. 2017.
Σειρά:Springer Series in Pharmaceutical Statistics,
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04800nam a2200541 4500
001 978-3-319-73770-6
003 DE-He213
005 20191026101920.0
007 cr nn 008mamaa
008 180522s2017 gw | s |||| 0|eng d
020 |a 9783319737706  |9 978-3-319-73770-6 
024 7 |a 10.1007/978-3-319-73770-6  |2 doi 
040 |d GrThAP 
050 4 |a QA276-280 
072 7 |a PBT  |2 bicssc 
072 7 |a MED090000  |2 bisacsh 
072 7 |a PBT  |2 thema 
072 7 |a MBNS  |2 thema 
082 0 4 |a 519.5  |2 23 
100 1 |a Rauch, Geraldine.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Planning and Analyzing Clinical Trials with Composite Endpoints  |h [electronic resource] /  |c by Geraldine Rauch, Svenja Schüler, Meinhard Kieser. 
250 |a 1st ed. 2017. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2017. 
300 |a XVI, 255 p. 9 illus., 2 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Springer Series in Pharmaceutical Statistics,  |x 2366-8695 
505 0 |a Preface -- Contents -- Part I General Introduction to Composite Endpoints -- 1 Definition and Rationale -- 2 Challenges of Composite Endpoints -- 3 Guideline View - Recommendations and Requirements -- 4 Clinical Trial Examples -- Part II Confirmatory Test Problem for a Single (Composite) Endpoint -- 5 The Single-Stage Design -- 6 Group-Sequential and Adaptive Designs -- 7 Related Software Code -- Part III Confirmatory Multiple Test Problem -- 8 Correlation Between Test Statistics -- 9 The Single-Stage Design -- 10 Group-Sequential and Adaptive Designs -- 11 Related Software Code -- Part IV Confirmatory Test Problem for a Weighted Composite Endpoint -- 12 Weighted Binary Composite Endpoint -- Weighted Time-to-Event Composite Endpoint -- 14 OtherWeighted Effect Measures -- 15 Related Software Code -- Part V Descriptive and Confirmatory Evaluation of the Components -- 16 Descriptive Analysis of the Components -- 17 Supplementary Confirmatory Analyses of the Components -- 18 Related Software Code -- Part VI Illustrating Clinical Trial Examples -- 19 Clinical Trial Examples with Binary (Composite) Endpoints -- 20 Clinical Trial Examples with (Composite) Time-to-Event Endpoints. 
520 |a This book addresses the most important aspects of how to plan and evaluate clinical trials with a composite primary endpoint to guarantee a clinically meaningful and valid interpretation of the results. Composite endpoints are often used as primary efficacy variables for clinical trials, particularly in the fields of oncology and cardiology. These endpoints combine several variables of interest within a single composite measure, and as a result, all variables that are of major clinical relevance can be considered in the primary analysis without the need to adjust for multiplicity. Moreover, composite endpoints are intended to increase the size of the expected effects thus making clinical trials more powerful. The book offers practical advice for statisticians and medical experts involved in the planning and analysis of clinical trials. For readers who are mainly interested in the application of the methods, all the approaches are illustrated with real-world clinical trial examples, and the software codes required for fast and easy implementation are provided. The book also discusses all the methods in the context of relevant guidelines related to the topic. To benefit most from the book, readers should be familiar with the principles of clinical trials and basic statistical methods. 
650 0 |a Statistics . 
650 0 |a Biostatistics. 
650 0 |a Pharmaceutical technology. 
650 1 4 |a Statistics for Life Sciences, Medicine, Health Sciences.  |0 http://scigraph.springernature.com/things/product-market-codes/S17030 
650 2 4 |a Biostatistics.  |0 http://scigraph.springernature.com/things/product-market-codes/L15020 
650 2 4 |a Pharmaceutical Sciences/Technology.  |0 http://scigraph.springernature.com/things/product-market-codes/B21010 
700 1 |a Schüler, Svenja.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
700 1 |a Kieser, Meinhard.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319737690 
776 0 8 |i Printed edition:  |z 9783319737713 
776 0 8 |i Printed edition:  |z 9783030088552 
830 0 |a Springer Series in Pharmaceutical Statistics,  |x 2366-8695 
856 4 0 |u https://doi.org/10.1007/978-3-319-73770-6  |z Full Text via HEAL-Link 
912 |a ZDB-2-SMA 
950 |a Mathematics and Statistics (Springer-11649)